Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris
30 déc. 2019 07h05 HE
|
Sol-Gel Technologies Ltd.
All co-primary endpoints achieved in both Phase 3 clinical trialsTwyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over timeAdditional data to...
Sol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update
13 nov. 2019 07h05 HE
|
Sol-Gel Technologies Ltd.
Top-line generic product revenue of $4.7 million in the third quarterResults from TWIN Phase 3 trials in acne vulgaris remain on track for the fourth quarter of 2019 NESS ZIONA, Israel, Nov. 13,...
Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
16 oct. 2019 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology...
Sol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update
13 août 2019 07h05 HE
|
Sol-Gel Technologies Ltd.
Top-line generic product revenue of $7.8 millionTWIN Phase 3 trials are fully enrolled and remain on track to report results in 4Q19 NESS ZIONA, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel...
Sol-Gel Announces Pricing of Public Offering of Ordinary Shares
08 août 2019 08h10 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Hosting Analyst & Investor Day
25 juil. 2019 06h00 HE
|
Sol-Gel Technologies Ltd.
Notice of allowance for U.S. patent application extends TWIN patent protection to 2038Clinical study for SGT-210 in palmoplantar keratoderma (PPK) intended to begin in early 2020Webcast of Analyst...
Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea
08 juil. 2019 07h05 HE
|
Sol-Gel Technologies Ltd.
All primary and secondary endpoints achieved in both Phase 3 clinical trialsRapid efficacy demonstrated, with statistical significance reached as early as Week 2 compared with vehicleFavorable safety...
Sol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019
17 juin 2019 07h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo
28 mai 2019 09h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in June
23 mai 2019 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...